- CA$29.26m
- CA$121.11m
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment
Brief: Resverlogix Enters Cooperation Agreement To Support Development Of Apabetalone For Covid-19 Patients
Brief: Resverlogix Enters into Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support Development of Apabetalone for COVID-19 Patients
Brief: Resverlogix In Active Discussions With Morocco’S Ministry Of Health For Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone
Brief: Resverlogix Receives Ethics Approval For Canadian Sites In Covid-19 Clinical Trial
Brief: Resverlogix Announces Management Change
Brief: Resverlogix And Eversana Announce Partnership To Support The Pending Launch Of The Initial Commercialization Of Apabetalone For Covid-19 In The United States And Canada
Brief: Health Canada Issues Resverlogix Authorization To Begin Immediate Clinical Studies Of Apabetalone For Covid-19
Brief: Resverlogix Announces Change In Fiscal Year-End To December 31
Brief: Resverlogix Announces Apabetalone Treatment Prior To Sars-Cov-2 (Covid-19) Exposure Significantly Reduces Viral Infection – Confirms Plans For Covid-19 Clinical Trial
Brief: Resverlogix Reports Filing Of New Intellectual Property On Key Renal Protection And Glucose Control Markers
Brief: Resverlogix Says A Second Publication Shortlists Co's Clinical Candidate Apabetalone For Its Potential Covid-19 Effectiveness
Brief: Resverlogix Announces $13 Million Private Placement
Brief: Resverlogix - Expect To File Its Interim Financial Statements And Related MD&A For Three Months Ended July 31, 2020 On/About October 5
Brief: Resverlogix Announces Publication On Apabetalone In Cardiovascular Therapeutics
Brief: Resverlogix Announces Extension Of Its Filing Calendar Based On Continuous Disclosure Exemption